Filing Summary
Filing identity and period: The supplied filing is Eyenovia, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 27, 2019. It is an annual report, not a standalone fourth-quarter report. The filing identifies the issuer as Eyenovia, Inc. (Nasdaq: EYEN), not Hyperion DeFi, Inc.
Business Context
Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose eye treatments using its Optejet piezo-print delivery technology. It had no approved products and had generated no product-sales revenue. Its strategy relies largely on the FDA’s 505(b)(2) development pathway for reformulated, established drugs.
Financial Performance and Position
| Metric | 2018 | 2017 |
|---|---|---|
| Product-sales revenue | None | None |
| Research and development expense | $11.12 million | $3.82 million |
| General and administrative expense | $6.14 million | $1.32 million |
| Operating loss | $17.26 million | $5.13 million |
| Net loss | $17.25 million | $5.13 million |
| Net loss per share, basic and diluted | $1.82 | $2.19 |
| Net cash used in operating activities | $13.11 million | $4.73 million |
- At December 31, 2018, cash was $19.73 million, working capital was $16.8 million, total assets were $20.02 million, and stockholders’ equity was $16.88 million.
- The company reported no debt outstanding at year-end. Revenue and operating margins are not meaningful because it had no product sales and incurred operating losses.
- Net cash provided by financing activities was $27.62 million in 2018, primarily from its January IPO and December follow-on offering. Management stated cash on hand was expected to fund operations for at least 12 months from the filing date; additional capital may be needed thereafter.
Changes, Outlook, and Risks
- Compared with 2017, 2018 R&D expense rose 191% and G&A expense rose 366%, reflecting increased clinical and development activity, hiring, stock compensation, and public-company costs. Net loss increased substantially as the business expanded.
- Pipeline outlook: MicroStat completed two Phase III studies with positive results; the company planned an NDA submission in 2020. MicroPine’s IND was accepted in February 2019, with a Phase III trial planned for 2019. MicroProst Phase III initiation was planned for 2019. MicroTears registration activities were planned for 2019, without a Phase III trial.
- These milestones were forward-looking plans, not assurances of regulatory approval or commercialization. The filing highlights clinical, regulatory, financing, manufacturing, market-acceptance, reimbursement, competition, and intellectual-property risks. Eyenovia expected expenses to increase and acknowledged it might need additional financing.
- A shareholder lawsuit related to the Corinthian asset purchase was settled in October 2018 for $600,000. Eyenovia paid $150,000; Corinthian’s insurer paid the remaining $450,000.
- Management reported that previously identified material weaknesses in internal control over financial reporting had been remediated and concluded controls were effective at December 31, 2018. The auditor did not attest to internal-control effectiveness; its opinion covered the financial statements.
- The company’s Asia licensing partner, Senju Pharmaceuticals, was entitled to royalties on licensed product sales; no royalties had been earned because there had been no commercial sales.
Most Important Facts to Verify
- Confirm the issuer and filing match the intended company: this document is Eyenovia, Inc. (EYEN), not Hyperion DeFi, Inc.
- Confirm the intended reporting period: the filing covers the full year ended December 31, 2018, rather than Q4 alone.
- Review the audited financial statements and cash-flow details, including the $13.11 million operating cash use and management’s stated 12-month cash runway.
- Check subsequent clinical and regulatory progress against the stated MicroStat, MicroPine, MicroProst, and MicroTears timelines.
- Assess future financing needs, potential share dilution, and the risks of clinical, regulatory, manufacturing, and commercialization delays.